1. |
宋璐, 夏冰. 溃疡性结肠炎发病机制及其诊断[J]. 中国实用内科杂志, 2010, 30(11):1056-1058.
|
2. |
Masoodi I, Tijjani BM, Wani H, et al. Biomarkers in the manag-ement of ulcerative colitis:a brief review[J]. Ger Med Sci, 2011,.
|
3. |
中华医学会消化病学分会炎症性肠病协作组. 中国炎症性肠病诊断治疗规范的共识意见[J]. 中华内科杂志, 2008, 47(1):73-79.
|
4. |
Truelove SC, Witts LJ. Cortisone in ulcerative colitis;final reporton a therapeutic trial[J]. Br BMJ J, 1955, 2(4947):1041-1048.
|
5. |
Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology, 2011, 140(6):1785-1794.
|
6. |
Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells[J]. Bull Eur Physiopathol Respir, 1980, 16 Suppl:273-282.
|
7. |
Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macrophage subset in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes[J]. Gut, 1994, 35(5):669-674.
|
8. |
Røseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein[J]. Digestion, 1997, 58(2):176-180.
|
9. |
:Doc03.
|
10. |
Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease[J]. Dig Liver Dis, 2009, 41(1):56-66.
|
11. |
沈姞, 李俊霞, 王化虹, 等. 粪便钙卫蛋白对溃疡性结肠炎的诊断及预测复发的价值[J]. 肠外与肠内营养, 2011, 18(5):272-276.
|
12. |
马列婷, 王亚文, 乔文. 粪便钙卫蛋白对溃疡性结肠炎诊断的临床价值[J]. 西安交通大学学报:医学版, 2008, 29(3):321-323.
|
13. |
Amati L, Passeri ME, Selicato F, et al. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease[J]. Immunopharmacol Immunotoxicol, 2006, 28(4):665-681.
|
14. |
Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease[J]. Gut, 2005, 54(3):364-368.
|
15. |
Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease[J]. Gastroenterology, 2000, 119(1):15-22.
|
16. |
张颖, 王英德. 粪便钙卫蛋白、抗中性粒细胞胞浆抗体检测在溃疡性结肠炎诊断中的价值比较[J]. 中华临床医师杂志:电子版, 2012, 6(6):1620-1622.
|
17. |
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD:useful, magic, or unnecessary toys?[J]. Gut, 2006, 55(3):426-431.
|
18. |
Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation ofC-reactive protein with clinical, endoscopic, histologic, and radio-graphic activity in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2005, 11(8):707-712.
|
19. |
Manz M, Burri E, Rothen C, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort:an observational study[J]. BMC Gastroenterol, 2012, 12:5.
|
20. |
Erbayrak M, Turkay C, Eraslan E, et al. The role of fecal calprotectin in investigating inflammatory bowel diseases[J]. Clinics,.
|
21. |
Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis:correlation of the rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes[J]. Inflamm Bowel Dis, 2009, 15(12):1851-1858.
|
22. |
Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease[J]. Br J Surg, 2009, 96(6):663-674.
|
23. |
Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality[J]. Lancet, 2000, 356(9244):1783-1784.
|
24. |
Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases:a meta-analysis of pros-pective studies[J]. Inflamm Bowel Dis, 2012, 18(10):1894-1899.
|
25. |
Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes[J]. Inflamm Bowel Dis, 2013, 19(2):332-341.
|
26. |
欧阳钦. 溃疡性结肠炎的治疗[J]. 中国实用内科杂志, 2010, 30(4):383-385.
|
27. |
, 64(5):421-425.
|